• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RUNX2通过促进谷氨酰胺代谢增强膀胱癌进展。

RUNX2 enhances bladder cancer progression by promoting glutamine metabolism.

作者信息

Huang Zhigang, Liu Bin, Li Xiaoju, Jin Chenghua, Hu Quansen, Zhao Zhiwei, Sun Yimin, Wang Qian

机构信息

Department of Urology, The First Affiliated Hospital of Yangtze University, JingZhou, Hubei Province, China.

Department of Traditional Chinese Medicine, The First Affiliated Hospital of Yangtze University, JingZhou, Hubei Province, China.

出版信息

Neoplasia. 2025 Feb;60:101120. doi: 10.1016/j.neo.2024.101120. Epub 2024 Dec 28.

DOI:10.1016/j.neo.2024.101120
PMID:39733689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11743350/
Abstract

Bladder cancer is a prevalent malignancy within the urinary system. Prior research has suggested that glutamine metabolism plays a crucial role in driving bladder cancer progression. However, the precise molecular mechanism governing glutamine metabolism in bladder cancer is still inadequately understood. The research revealed a significant correlation between high levels of RUNX2 and SLC7A6 and advanced clinical stage, as well as poor prognosis, in bladder cancer patients. Furthermore, manipulating the levels of RUNX2 through overexpression or silencing demonstrated a significant impact on glutamine and bladder cancer progression. Mechanically, RUNX2 regulates the transcription of SLC7A6, resulting in enhanced glutamine metabolism and promoting the progression of bladder cancer. Overall, this research affirms the crucial function of RUNX2 as a key transcription factor to promoting glutamine and cancer development through modulation of SLC7A6. Targeting RUNX2 could represent a promising therapeutic approach for addressing aberrant glutamine metabolism in bladder cancer.

摘要

膀胱癌是泌尿系统中一种常见的恶性肿瘤。先前的研究表明，谷氨酰胺代谢在推动膀胱癌进展中起着关键作用。然而，膀胱癌中谷氨酰胺代谢的精确分子机制仍未得到充分了解。该研究揭示，RUNX2和SLC7A6的高水平与膀胱癌患者的晚期临床分期以及不良预后之间存在显著相关性。此外，通过过表达或沉默来操纵RUNX2的水平对谷氨酰胺和膀胱癌进展显示出显著影响。从机制上讲，RUNX2调节SLC7A6的转录，导致谷氨酰胺代谢增强并促进膀胱癌进展。总体而言，这项研究证实了RUNX2作为关键转录因子通过调节SLC7A6促进谷氨酰胺代谢和癌症发展的关键功能。靶向RUNX2可能是解决膀胱癌中异常谷氨酰胺代谢的一种有前景的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/2255480d17d9/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/905647eb0b94/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/9a52c10a0362/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/11f491fa4e91/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/5280035be3fc/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/a1f8aed10aed/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/357ca8aa0254/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/2255480d17d9/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/905647eb0b94/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/9a52c10a0362/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/11f491fa4e91/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/5280035be3fc/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/a1f8aed10aed/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/357ca8aa0254/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3189/11743350/2255480d17d9/gr7.jpg

相似文献

1
RUNX2 enhances bladder cancer progression by promoting glutamine metabolism.RUNX2通过促进谷氨酰胺代谢增强膀胱癌进展。
Neoplasia. 2025 Feb;60:101120. doi: 10.1016/j.neo.2024.101120. Epub 2024 Dec 28.
2
The novel ferroptosis-inducing molecule can inhibit the progression of BC by regulating the ubiquitination of UHRF1.这种新型的铁死亡诱导分子可通过调节UHRF1的泛素化来抑制乳腺癌的进展。
Epigenomics. 2025 Jul 16:1-15. doi: 10.1080/17501911.2025.2530923.
3
SIGMAR1 screened by a GPCR-related classifier regulates endoplasmic reticulum stress in bladder cancer.通过GPCR相关分类器筛选出的SIGMAR1调节膀胱癌中的内质网应激。
J Transl Med. 2025 Apr 10;23(1):417. doi: 10.1186/s12967-025-06393-7.
4
Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.多组学分析揭示了 IGF2BP3/SPHK1 信号在肌层浸润性膀胱癌肿瘤干细胞中对预后和免疫治疗反应的预测价值。
J Transl Med. 2024 Oct 4;22(1):900. doi: 10.1186/s12967-024-05685-8.
5
The N6-methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression.N6-甲基腺苷阅读器IGF2BP3通过增强HSP90AB1的表达促进膀胱癌进展。
FEBS J. 2025 Jul;292(13):3477-3493. doi: 10.1111/febs.70068. Epub 2025 Mar 19.
6
RUNX2 mediated epithelial mesenchymal transition induced by TGF beta and Smad signaling promotes malignant progression in glioma.RUNX2介导的由转化生长因子β和Smad信号传导诱导的上皮-间质转化促进胶质瘤的恶性进展。
Sci Rep. 2025 Jul 23;15(1):26781. doi: 10.1038/s41598-025-09167-9.
7
Smoking promotes the progression of bladder cancer through FOXM1/CKAP2L axis.吸烟通过FOXM1/CKAP2L轴促进膀胱癌进展。
J Transl Med. 2025 Jul 11;23(1):785. doi: 10.1186/s12967-025-06835-2.
8
m6A-YTHDF1 Mediated Regulation of GRIN2D in Bladder Cancer Progression and Aerobic Glycolysis.m6A-YTHDF1介导的GRIN2D在膀胱癌进展及有氧糖酵解中的调控作用
Biochem Genet. 2024 Jun 29. doi: 10.1007/s10528-024-10875-6.
9
SRSF1-mediated alternative splicing regulates bladder cancer progression and cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis.SRSF1介导的可变剪接通过HIF1A/BNIP3/线粒体自噬轴调节膀胱癌进展和顺铂敏感性。
J Transl Med. 2025 May 22;23(1):571. doi: 10.1186/s12967-025-06547-7.
10
SFXN1 promotes bladder cancer metastasis by restraining PINK1-dependent mitophagy.SFXN1通过抑制PINK1依赖的线粒体自噬促进膀胱癌转移。
Oncogene. 2025 Jun 4. doi: 10.1038/s41388-025-03460-7.

本文引用的文献

1
TGF-β downstream of Smad3 and MAPK signaling antagonistically regulate the viability and partial epithelial-mesenchymal transition of liver progenitor cells.Smad3和丝裂原活化蛋白激酶（MAPK）信号下游的转化生长因子-β（TGF-β）对肝祖细胞的活力和部分上皮-间质转化起拮抗调节作用。
Aging (Albany NY). 2024 Apr 5;16(7):6588-6612. doi: 10.18632/aging.205725.
2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
CENPA promotes glutamine metabolism and tumor progression by up-regulating SLC38A1 in endometrial cancer.
在子宫内膜癌中，CENPA通过上调SLC38A1促进谷氨酰胺代谢和肿瘤进展。
Cell Signal. 2024 May;117:111110. doi: 10.1016/j.cellsig.2024.111110. Epub 2024 Feb 20.
4
Advances in diagnosis and treatment of bladder cancer.膀胱癌的诊断与治疗进展。
BMJ. 2024 Feb 12;384:e076743. doi: 10.1136/bmj-2023-076743.
5
RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells.RUNX2 通过 TGF-β 通路调节乳腺癌干细胞促使三阴性乳腺癌耐药。
Neoplasia. 2024 Feb;48:100967. doi: 10.1016/j.neo.2024.100967. Epub 2024 Jan 13.
6
Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment.甲硫氨酸协调顺铂耐药膀胱癌微环境中的代谢脆弱性。
Cell Death Dis. 2023 Aug 15;14(8):525. doi: 10.1038/s41419-023-06050-1.
7
LncRNA PVT1 Confers Cisplatin Resistance of Esophageal Cancer Cells through Modulating the miR-181a-5p-Glutaminase (GLS) Axis.长链非编码 RNA PVT1 通过调节 miR-181a-5p-谷氨酰胺酶（GLS）轴赋予食管癌细胞顺铂耐药性。
Nutr Cancer. 2023;75(8):1646-1657. doi: 10.1080/01635581.2023.2166540. Epub 2023 Jul 4.
8
Epigenetic and Immunological Features of Bladder Cancer.膀胱癌的表观遗传和免疫学特征。
Int J Mol Sci. 2023 Jun 7;24(12):9854. doi: 10.3390/ijms24129854.
9
RUNX2 promotes gastric cancer progression through the transcriptional activation of MGAT5 and MMP13.RUNX2通过转录激活MGAT5和MMP13促进胃癌进展。
Front Oncol. 2023 May 15;13:1133476. doi: 10.3389/fonc.2023.1133476. eCollection 2023.
10
RUNX2 and Cancer.RUNX2 与癌症。
Int J Mol Sci. 2023 Apr 10;24(8):7001. doi: 10.3390/ijms24087001.